



Patent
207/145

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:)	Group Art Unit:	To be
ANDREW C. HIATT and FLOYD ROSE)		Assigned
Serial No. 08/300,484)	Examiner:	To be Assigned
Filed: September 1, 1994)		
For: ENZYME CATALYZED TEMPLATE-)		
INDEPENDENT CREATION OF)		
PHOSPHODIESTER BONDS USING)		
PROTECTED NUCLEOTIDES)		

MAR 15 1994

STATEMENT UNDER 37 C.F.R. § 1.821 (F)

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821 (e), (f) and (g), or § 1.825 (d) and (b) respectively, are the same.

Respectfully submitted,

LYON & LYON

By: Jeffrey W. Guise
Jeffrey W. Guise
Registration No. 34,613

First Interstate World Center
633 West Fifth Street
Suite 4700
Los Angeles, CA 90071
(213) 489-1600

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231


Feb. 6, 1995
Date of Deposit

Kim Arnold-Cabeller
Name of Person Mailing Paper
KACabeller
Signature of Person Mailing Paper

Best Available Copy

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. Other: _____

Applicant must provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123
 For CRF submission help, call (703) 308-4212
 For PatentIn software help, call (703) 308-6856

Please return a copy of this notice with your response.

Best Available Copy